Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 13 September 2017, 10:00 to 13:00

Venue: National Institute for Health and Care Excellence
       Level 1A, City Tower
       Piccadilly Plaza
       Manchester
       M1 4BT

Present: 1. Professor Peter Selby (Chair) Present for all notes
         2. Mr Kamal Balakrishnan Present for all notes
         3. Mr Michael Chambers Present for all notes
         4. Mr David Chandler Present for all notes
         5. Mrs Gail Coster Present for all notes
         6. Mr John P Hampson Present for all notes
         7. Dr Nigel Langford Present for all notes
         8. Professor Andrea Manca Present for all notes
         9. Mr Richard Nicholas Present for all notes
        10. Professor Stephen O’Brien Present for all notes
        11. Professor Matt Stevenson Present for all notes
        12. Dr Paul Tappenden Present for all notes
        13. Mr Robert Walton Present for all notes
        14. Dr Derek Ward Present for all notes
        15. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, Present for all notes
        National Institute for
        Health and Care
        Excellence

Frances Sutcliffe Associate Director, Present for all notes
        National Institute for
        Health and Care
        Excellence

Stephanie Yates Project Manager, Present for all notes
        National Institute for
        Health and Care
        Excellence

Mandy Tonkinson Administrator, National Present for all notes
        Institute for Health and
        Care Excellence

Jessica Maloney Technical Analyst, Present for notes 5 to 13
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

2. The Chair informed the Committee of the non-public observers at this meeting: Maroulla Whitely and Sonali Sanghvi.

3. Apologies were received from Professor Kathryn Abel, Professor Andrew Renehan and Professor Andrew Stevens.

Any other business

4. None

Appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

Part 1 – Open session

5. The Chair welcomed the invited experts: Peter Clark, Sophie Beale, James Mahon and Sarah Nevitt to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Roche to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Peter Selby, Mr Kamal Balakrishnan, Mr David Chandler, Mrs Gail Coster, Mr John P Hampson, Dr Nigel Langford, Professor Andrea Manca, Professor
Stephen O’Brien, Professor Matt Stevenson, Dr Paul Tappenden, Mr Robert Walton, Dr Derek Ward and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

7.2. Mr Michael Chambers declared a personal non-specific financial interest as he has received payment from Roche Pharmaceuticals on topics unrelated to this appraisal topic.

7.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

7.3. Mr Richard Nicholas declared a personal financial non-specific interest for his involvement in clinical trials for a different Roche product ocrelizumab. He also declared a personal financial non-specific interest as he has received honorarium for participating in advisory boards for Sanofi (a possible comparator company).

7.3.1. It was agreed that this declaration would not prevent Mr Richard Nicholas from participating in this section of the meeting.

7.4. Dr Prithwiraj Das is absent due to conflicts. He is employed by Boehringer Ingelheim which is a comparator company in this appraisal.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings).
Act 1960)" and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Date, time and venue of the next meeting**

17. Thursday 12 October 2017 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.